CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 153 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.08 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $154,244 | +21.7% | 10,345 | -10.7% | 0.00% | – |
| Q2 2023 | $126,790 | +153.6% | 11,579 | -15.4% | 0.00% | – |
| Q3 2021 | $50,000 | -27.5% | 13,684 | -14.0% | 0.00% | – |
| Q2 2021 | $69,000 | 0.0% | 15,903 | +3.9% | 0.00% | – |
| Q1 2021 | $69,000 | -15.9% | 15,301 | +7.6% | 0.00% | – |
| Q4 2020 | $82,000 | +164.5% | 14,224 | -31.2% | 0.00% | – |
| Q1 2020 | $31,000 | +55.0% | 20,686 | +106.3% | 0.00% | – |
| Q4 2019 | $20,000 | -94.2% | 10,028 | -67.9% | 0.00% | – |
| Q3 2018 | $347,000 | -15.8% | 31,276 | +1.9% | 0.00% | – |
| Q2 2018 | $412,000 | – | 30,703 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,254,502 | $20,741,000 | 14.54% |
| Versant Venture Management, LLC | 1,048,601 | $9,647,127,000 | 10.15% |
| Abingworth LLP | 1,147,077 | $10,553,000 | 7.65% |
| Omega Fund Management, LLC | 551,477 | $5,074,000 | 3.67% |
| Opaleye Management Inc. | 665,000 | $6,118,000 | 1.96% |
| DAFNA Capital Management LLC | 361,164 | $3,323,000 | 1.79% |
| Boxer Capital, LLC | 1,012,986 | $9,319,000 | 1.70% |
| Foresite Capital Management III, LLC | 600,000 | $5,520,000 | 1.55% |
| NEXTHERA CAPITAL LP | 536,568 | $4,936,000 | 0.91% |
| Perceptive Advisors | 2,685,882 | $24,710,000 | 0.82% |